M Ganten - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

M Ganten

Showing results (41-50 of 46) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 46 results.

Hepatology (Baltimore, Md.)|January 17, 2013

Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4BKatharina Esser-Nobis, Inés Romero-Brey, Tom M Ganten, et al.

Cancer Cell|March 11, 2008

Yes and PI3K bind CD95 to signal invasion of glioblastomaSusanne Kleber, Ignacio Sancho-Martinez, Benedict Wiestler, et al.

Journal of Hepatology|March 9, 2016

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER studyMichael Bitzer, Marius Horger, Edoardo G Giannini, et al.

Cancer Cell|April 7, 2015

Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasisSilvia von Karstedt, Annalisa Conti, Max Nobis, et al.

Annals of Surgery|September 5, 2020

mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active TumorsAndreas A Schnitzbauer, Natalie Filmann, René Adam, et al.

Transplantation|November 12, 2015

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 TrialEdward K Geissler, Andreas A Schnitzbauer, Carl Zülke, et al.

Pageof 5

Search research articles

Showing results (41-50 of 46) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 46 results.

Hepatology (Baltimore, Md.)|January 17, 2013

Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4BKatharina Esser-Nobis, Inés Romero-Brey, Tom M Ganten, et al.

Cancer Cell|March 11, 2008

Yes and PI3K bind CD95 to signal invasion of glioblastomaSusanne Kleber, Ignacio Sancho-Martinez, Benedict Wiestler, et al.

Journal of Hepatology|March 9, 2016

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER studyMichael Bitzer, Marius Horger, Edoardo G Giannini, et al.

Cancer Cell|April 7, 2015

Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasisSilvia von Karstedt, Annalisa Conti, Max Nobis, et al.

Annals of Surgery|September 5, 2020

mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active TumorsAndreas A Schnitzbauer, Natalie Filmann, René Adam, et al.

Transplantation|November 12, 2015

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 TrialEdward K Geissler, Andreas A Schnitzbauer, Carl Zülke, et al.

Pageof 5